503 related articles for article (PubMed ID: 23215027)
21. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions.
Vijayaraghavalu S; Peetla C; Lu S; Labhasetwar V
Mol Pharm; 2012 Sep; 9(9):2730-42. PubMed ID: 22817326
[TBL] [Abstract][Full Text] [Related]
22. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
23. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
25. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
Mirza S; Sharma G; Pandya P; Ralhan R
Mol Cell Biochem; 2010 Sep; 342(1-2):101-9. PubMed ID: 20455010
[TBL] [Abstract][Full Text] [Related]
26. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
28. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
30. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
[TBL] [Abstract][Full Text] [Related]
31. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
32. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines.
Jadhav V; Ray P; Sachdeva G; Bhatt P
Life Sci; 2016 Mar; 148():41-52. PubMed ID: 26883975
[TBL] [Abstract][Full Text] [Related]
33. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
[TBL] [Abstract][Full Text] [Related]
38. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
[TBL] [Abstract][Full Text] [Related]
39. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
40. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
